Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2007

Stratagene Gains Rights to over 150 microRNA Sequences

  • Stratagene obtained the last of the four co-exclusive licenses to more than 150 microRNA sequences available from Max Planck Innovation, the technology transfer agency of the Max Planck Society.

    "The potential of these sequences, when paired with our proprietary FullVelocity technology, should allow us to develop important detection tests for the molecular diagnostics marketplace," says Joseph A. Sorge, M.D., chairman and CEO.

    Under the terms of the agreement, Stratagene will have the right to use the microRNA sequences for the development, manufacture, and sale of molecular diagnostic kits. Stratagene reports that it is particularly interested in the association of microRNAs with cancer.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »